Margaret Kaczor
Stock Analyst at William Blair
(0.59)
# 3,904
Out of 4,862 analysts
24
Total ratings
35.71%
Success rate
-17.12%
Average return
Main Sectors:
Stocks Rated by Margaret Kaczor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $17.08 | - | 2 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Upgrades: Outperform | n/a | $5.86 | - | 3 | Jan 14, 2025 | |
| CBLL CeriBell | Initiates: Outperform | n/a | $17.27 | - | 1 | Nov 5, 2024 | |
| STIM Neuronetics | Downgrades: Market Perform | n/a | $3.80 | - | 4 | Aug 12, 2024 | |
| INGN Inogen | Upgrades: Outperform | n/a | $6.25 | - | 5 | Feb 15, 2024 | |
| SKIN The Beauty Health Company | Downgrades: Market Perform | n/a | $1.53 | - | 2 | Nov 14, 2023 | |
| DVA DaVita | Downgrades: Market Perform | n/a | $136.12 | - | 2 | Sep 11, 2019 | |
| MDT Medtronic | Assumes: Market Perform | n/a | $87.27 | - | 1 | Jun 6, 2018 | |
| ABT Abbott Laboratories | Upgrades: Outperform | n/a | $135.62 | - | 3 | Jan 25, 2018 | |
| DXCM DexCom | Initiates: Outperform | n/a | $81.99 | - | 1 | Apr 27, 2017 |
STAAR Surgical Company
Feb 12, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $17.08
Upside: -
CVRx, Inc.
Jan 14, 2025
Upgrades: Outperform
Price Target: n/a
Current: $5.86
Upside: -
CeriBell
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.27
Upside: -
Neuronetics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.80
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $6.25
Upside: -
The Beauty Health Company
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.53
Upside: -
DaVita
Sep 11, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $136.12
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $87.27
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $135.62
Upside: -
DexCom
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $81.99
Upside: -